Den 20 oktober presenterade Karin Agerman, Chief Research & Development Officer på CombiGene på ATMP Swedens webinar Manufacturing of Gene Therapy Products in Sweden
On October 20, Karin Agerman, Chief Research & Development Officer at CombiGene presented on ATMP Sweden’s webinar Manufacturing of Gene Therapy Products in Sweden. Karin gave her views on the production of gene therapies in Sweden under the heading A small company’s perspective on manufacture of in vivo gene therapy in Sweden for clinical trial.
If you didn’t have the opportunity to follow the presentation live, you can now view it here https://www.youtube.com/watch?v=SYbm4a883JY&t (abaut 22 minuts in the presentation)
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.